ArticleNature immunology2024
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8
Abstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Benchmarking AlphaFold and related deep learning approaches for modeling antibody and TCR antigen recognition.bioRxiv : the preprint server for biology · 2026Article
- Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.NPJ vaccines · 2026Article
- Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection.Frontiers in medicine · 2026Review
- Profiling of SARS-CoV-2 virus shedding, antibody neutralization, and T-cell receptor repertoires in a large, multi-center cohort of young adults with varied prior exposures.Frontiers in immunology · 2026Article
- TCR2HLA: Calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes.PLoS computational biology · 2026Article
- TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing.Nature methods · 2026Article
- RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges.Immunologic research · 2025Review
- TCR2HLA: calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes.bioRxiv : the preprint server for biology · 2025Article
- Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.The Journal of allergy and clinical immunology · 2025Article
- SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annual review of immunology · 2025Review
- Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine.Nature communications · 2025Article
- Tick-borne encephalitis virus variants drive distinct TCR repertoire alterations.Frontiers in immunology · 2025Article
- Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy.Theranostics · 2025Review
- Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation.Frontiers in immunology · 2025Article
- The immunological impact of revaccination in a hybrid-immune world.Frontiers in immunology · 2025Review
- Machine learning-driven dissection of the obesity-ccRCC interface: FCGR2A emerges as a central coordinator of tumor-immune crosstalk.Frontiers in oncology · 2025Article
- Distinct characteristics of T cell receptor repertoire associated with the SARS-CoV-2 reinfection.Frontiers in immunology · 2025Article
- Bioinformatic Tools for Studying the Cellular Immune Response to SARS-CoV-2, Vaccine Efficacy, and Future Pandemics at the Global Population Level.International journal of molecular sciences · 2024Review
- The characteristics of TCR CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccine recipients.Virulence · 2024Review
- Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity.Current opinion in virology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Emily S Ford *Department of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7358-798X
Koshlan Mayer-Blackwell *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Lichen Jing *Department of Medicine, University of Washington, Seattle, WA, USA.
Kerry J LaingDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9245-5325
Anton M SholukhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0498-9162
Russell St GermainVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Emily L BossardVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0009-0006-4466-0336
Hong XieDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Thomas H PulliamDepartment of Medicine, University of Washington, Seattle, WA, USA.
Saumya JaniDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1212-1961
Stacy SelkeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Carlissa J BurrowDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0009-0003-7176-3486
Christopher L McClurkanDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0009-0008-0473-4366
Anna WaldDepartment of Medicine, University of Washington, Seattle, WA, USA.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7443-0527
Michael R HolbrookIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-0824-2667
Brett EatonIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3060-2913
Elizabeth EudyIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-7583-9319
Michael MurphyIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
Elena PostnikovaIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-0275-2148
Harlan S RobinsAdaptive Biotechnologies, Seattle, WA, USA.
Rebecca ElyanowAdaptive Biotechnologies, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8877-7188
Rachel M GittelmanAdaptive Biotechnologies, Seattle, WA, USA.
Matyas EcsediClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1341-8070
Elise WilcoxClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2899-4110
Aude G ChapuisDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9574-5448
Andrew Fiore-GartlandVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7627-2166
David M KoelleDepartment of Medicine, University of Washington, Seattle, WA, USA. dkoelle@medicine.washington.edu.ORCID http://orcid.org/0000-0003-1255-9023
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MUnderstand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Ted A Gooley · 2019 to 2026
$22.7MInterdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7MDECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHCR01AI136514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul G. Thomas · 2018 to 2026
$6.9MLarge Scale T Cell Epitope Discovery: Local and Systemic T cell Response to Herpes Simplex Virus75N93019C00063 · NIAID · UNIVERSITY OF WASHINGTON · PI MYER, TIM · 2019 to 2023
$5.5MHarnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus InfectionsR01AI134878 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COREY, LAWRENCE · 2018 to 2022
$3.4MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MPPE RequestS10AI174104 · NIAID · FRED HUTCHINSON CANCER CENTER · PI COREY, LAWRENCE · 2023 to 2023
$1.4MHSV-2 specificity and phenotyping of tissue-based T cells in genital skin biopsies of HSV-2 reactivationK08AI148588 · NIAID · UNIVERSITY OF WASHINGTON · PI FORD, EMILY · 2020 to 2024
$947kC19 SARS-CoV-2-specific T cells in the infected nasel epitheliumR21AI163999 · NIAID · UNIVERSITY OF WASHINGTON · PI KOELLE, DAVID M · 2021 to 2022
$485kExhaustion mechanisms in Merkel cell polyomavirus-specific T cellsF30CA254168 · NCI · UNIVERSITY OF WASHINGTON · PI PULLIAM, THOMAS · 2020 to 2023
$168kNCI NIH HHS F30 CA254168NCI NIH HHS P01 CA225517NCI NIH HHS T32 CA080416NIAID NIH HHS 75N93019C00063NIAID NIH HHS HHSN272201800013CNIAID NIH HHS K08 AI148588NIAID NIH HHS R01 AI134878NIAID NIH HHS R01 AI136514NIAID NIH HHS R21 AI163999NIAID NIH HHS S10 AI174104NIAID NIH HHS UM1 AI068614NIH HHS S10 OD028685
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hybrid immunity is more protective than vaccination or previous infection alone. To investigate the kinetics of spike-reactive T (T
Indexed as
COVID-19SARS-CoV-2Antibodies, ViralCD8-Positive T-LymphocytesHumansReceptors, Antigen, T-Cell, alpha-betaRNA, MessengerVaccinationAntibodies, ViralReceptors, Antigen, T-Cell, alpha-betaRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.